The technology developed by Polytheragene finds its origin in some research carried out in two laboratories, one laboratory belonging to the university of Evry Val d’Essonne, and a laboratory of the French National Research Council (CNRS) at Orleans, working on the domain of the synthetic vectors for nucleic acid transfer (DNA and RNA), and hydrophobic therapeutics delivery.


Polytheragene is developing two new families of synthetic vectors: PTG1 devoted to overcome the two main limits of synthetic vectors: efficiency and cytotoxicity. As a result, PTG1 vectors show superior in vitro and ex vivo transfection efficiency. As for the PTG2 family it has been especially designed for the vectorization and biodistribution of hydrophobic therapeutically active molecules.


Polymeric molecules developed by Polytheragene are of low in vitro and in vivo toxicity. Upon request, they can be functionalized by fluorescent or spectroscopically active functions and/or by tags for targeting. PTG2 products can be adapted to vectorization of various molecules and favor their biodistribution. Functionalization is also possible.